The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Addeo, Raffaele; Caraglia, Michele

doi:10.1586/era.10.190

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is also evidence of synergism with Capecitabine, a pyrimidine analogue prodrug approved for metastatic breast cancer management [41, 54]. Sunitinib, a multikinase inhibitor (targets include VEGF-Rs, c-kit and PDGF-Rs), is also under investigation for its effects on BM in metastatic breast and renal cell carcinomas [64, 65, 69]. …”

Section: Treatment Strategies Against Metastatic Breast Cancers Inmentioning

confidence: 99%

Molecular Aspects of Breast Cancer Metastasis to the Brain

Saunus

Momeny

Simpson

et al. 2011

Genetics Research International

View full text Add to dashboard Cite

Our knowledge of the biology underlying the development of brain metastases (BM) from breast cancer has improved over the last decade due to large clinical epidemiological studies, animal models of metastasis, and the use of high-resolution gene expression profiling technologies. However, there are still major gaps in our understanding of the mechanisms utilized by breast cancer cells to colonize the brain microenvironment, thus our arsenal of therapies remains relatively nonspecific, and the prognosis for breast cancer patients with BM remains poor. Additional insights into these mechanisms are necessary to facilitate the development of new preventive and curative therapeutic regimens to block this fatal disease. This paper aims to provide a general overview for the readers of what has been achieved in this field of research and its translation into clinical practice to date and to highlight exciting new areas of research that promise to inform the development of new targeted therapies for BM.

show abstract

Section: Treatment Strategies Against Metastatic Breast Cancers Inmentioning

confidence: 99%

Molecular Aspects of Breast Cancer Metastasis to the Brain

Saunus

Momeny

Simpson

et al. 2011

Genetics Research International

View full text Add to dashboard Cite

show abstract

“…Clinical studies have shown that after oral administration, sunitinib could rapidly reach brain tissue . Sunitinib treatment has been shown as safe and efficient in brain metastasis of renal cell carcinoma , suggesting that sunitinib is able to penetrate the blood–brain barrier and reach central nervous system (CNS) . Interestingly, it has been reported that accumulation of sunitinib in the brain could be restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), two ATP‐binding cassette drug efflux transporters in the blood–brain barrier (BBB) .…”

Section: Introductionmentioning

confidence: 99%

Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide Overproduction

Cui

Zhang

et al. 2014

CNS Neurosci Ther

View full text Add to dashboard Cite

show abstract

“…Molecularly targeted agents are now available in the treatment of brain metastases, such as the oral tyrosine kinase inhibitor (TKI) lapatinib for HER-2-expressing breast cancer patients 29. These patients have a reported high risk of brain metastases, which may be due to the poor penetration through the BBB of the otherwise effective HER-2 targeting drug trastuzumab, in addition to the possibility that HER-2 –expressing breast cancer may be more biologically aggressive 29…”

Section: Introductionmentioning

confidence: 99%

Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy

Linnert

Iversen

Gehl³

2012

Radiology and Oncology

View full text Add to dashboard Cite

Background. Due to the advanced oncological treatments of cancer, an overall increase in cancer incidence, and better diagnostic tools, the incidence of brain metastases is on the rise. This review addresses the current treatment options for patients with multiple brain metastases, presenting electrochemotherapy (ECT) as one of the new experimental treatments for this group of patients.Conclusions. Neurosurgery, stereotactic surgery, and whole-brain radiotherapy are the evidence-based treatments that can be applied for patients with multiple brain metastases. Treatment with chemotherapy and molecularly targeted agents may also be warranted. Several experimental treatments are emerging, one of which is ECT, an effective cancer treatment comprising electric pulses given by electrodes in the tumor tissue, causing electroporation of the cell membrane, and thereby augmenting uptake and the cytotoxicity of the chemotherapeutic drug bleomycin by 300 times. Preclinical data are promising and the first patient has been treated in an ongoing clinical trial for patients with brain metastases. Perspectives for ECT in the brain include treatment of primary and secondary brain tumors as well as soft tissue metastases elsewhere.

show abstract

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Cited by 11 publications

References 27 publications

Molecular Aspects of Breast Cancer Metastasis to the Brain

Molecular Aspects of Breast Cancer Metastasis to the Brain

Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide Overproduction

Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy

Contact Info

Product

Resources

About